文献速递糖尿病

地中海高心血管风险人群血浆酰基肉碱与2型糖尿病风险

Plasma Acylcarnitines and Risk of Type 2 Diabetes in a Mediterranean Population at High Cardiovascular Risk.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

在PREDIMED研究的事例队列中,包括251例新发2型糖尿病和694名随机基线参与者(随访3.8年),基线及1年酰基肉碱变化与2型糖尿病风险独立相关,但将酰基肉碱加入传统风险因素模型未显著改善预测的曲线下面积(0.86至0.88,P=0.61)。

要点

  • 短链和长链酰基肉碱谱与高心血管风险人群的2型糖尿病风险独立相关。
  • 包含酰基肉碱的预测模型风险比传统模型更高,但C统计量无显著改善。
  • 1年C4OH-肉碱每增加1个标准差与2型糖尿病风险升高相关(HR 1.44,95%CI 1.03-2.01)。

核心结论

  • 以短链和长链酰基肉碱为主的酰基肉碱谱与高心血管风险参与者的2型糖尿病风险显著相关。
  • 将酰基肉碱加入包含空腹血糖的传统风险因素模型未显著改善2型糖尿病预测的C统计量。

研究设计与样本

  • 在PREDIMED研究内设计的事例队列研究,纳入所有新发2型糖尿病病例(n=251)和694名随机选择的基线参与者,随访3.8年。
  • 采用液相色谱-串联质谱靶向方法测量血浆酰基肉碱,使用加权Cox回归模型检验基线及1年变化与2型糖尿病风险的关联。
  • 使用弹性净回归筛选用于2型糖尿病预测的酰基肉碱,并通过交叉验证方法计算加权评分。

主要发现

  • 预测模型评分每增加1个标准差,传统模型的风险比为4.03(95%CI 3.00-5.42;P<0.001),包含酰基肉碱的模型为4.85(95%CI 3.65-6.45;P<0.001)。
  • 归因于酰基肉碱的风险比为1.33(95%CI 1.08-1.63;P<0.001)。
  • 将酰基肉碱纳入模型未显著改善受试者工作特征曲线下面积(0.86至0.88,P=0.61)。
  • 1年C4OH-肉碱每增加1个标准差与2型糖尿病风险升高相关(HR 1.44,95%CI 1.03-2.01)。

临床怎么用

  • 酰基肉碱谱或有助于识别高心血管风险人群中2型糖尿病风险较高的个体,但尚不能替代传统预测模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The potential associations between acylcarnitine profiles and incidence of type 2 diabetes (T2D) and whether acylcarnitines can be used to improve diabetes prediction remain unclear. OBJECTIVE: To evaluate the associations between baseline and 1-year changes in acylcarnitines and their diabetes predictive ability beyond traditional risk factors. DESIGN, SETTING, AND PARTICIPANTS: We designed a case-cohort study within the PREDIMED Study including all incident cases of T2D (n = 251) and 694 randomly selected participants at baseline (follow-up, 3.8 years). Plasma acylcarnitines were measured using a targeted approach by liquid chromatography-tandem mass spectrometry. We tested the associations between baseline and 1-year changes in individual acylcarnitines and T2D risk using weighted Cox regression models. We used elastic net regressions to select acylcarnitines for T2D prediction and compute a weighted score using a cross-validation approach. RESULTS: An acylcarnitine profile, especially including short- and long-chain acylcarnitines, was significantly associated with a higher risk of T2D independent of traditional risk factors. The relative risks of T2D per SD increment of the predictive model scores were 4.03 (95% CI, 3.00 to 5.42; P < 0.001) for the conventional model and 4.85 (95% CI, 3.65 to 6.45; P < 0.001) for the model including acylcarnitines, with a hazard ratio of 1.33 (95% CI, 1.08 to 1.63; P < 0.001) attributed to the acylcarnitines. Including the acylcarnitines into the model did not significantly improve the area under the receiver operator characteristic curve (0.86 to 0.88, P = 0.61). A 1-year increase in C4OH-carnitine was associated with higher risk of T2D [per SD increment, 1.44 (1.03 to 2.01)]. CONCLUSIONS: An acylcarnitine profile, mainly including short- and long-chain acylcarnitines, was significantly associated with higher T2D risk in participants at high cardiovascular risk. The inclusion of acylcarnitines into the model did not significantly improve the T2D prediction C-statistics beyond traditional risk factors, including fasting glucose.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Guasch-Ferré M, Ruiz-Canela M, Li J, et al. Plasma Acylcarnitines and Risk of Type 2 Diabetes in a Mediterranean Population at High Cardiovascular Risk. J Clin Endocrinol Metab. 2019. PMID: 30423132. doi:10.1210/jc.2018-01000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。